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Indeed, advances in science have had 
a great impact, not only on the ability to 
discover new drug molecules, but also on 
research undertaken to assure their quality, 
safety and efficacy. The pharmaceutical 
industry has an excellent track record in this 
regard but is a victim of its own success, 
since society sometimes expects the industry 
to produce medicinal products with the 
same ease as a conjuror. Such a perspective 
has, inevitably, led to certain unrealistic 
expectations when considering the effect 
that the market prices of these medicines 
have on their accessibility.
Introduction
The discovery and development of 
medicinal products is expensive and time-
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consuming. The Pharmaceutical Research and 
Manufacturers of America (PhRMA) quote 
the time required to develop a medicinal 
product, from drug discovery to market 
launch, as lasting from 10 to 15 years.1 The 
process is, moreover, characterized by a 
high attrition rate: only one in ten thousand 
molecules entering drug discovery becomes 
a marketable product1, with the lowest 
chances of success being registered in the 
phases of preclinical development (40%) 
and phase II clinical trials (50%).2 The 
costs of producing a successful marketable 
product - approximately €980 million in 
20061 – have been described as “impressively 
large numbers, usually associated with a 
purchase of jet fighters”.3 This figure takes 
into account both the cost of the successful 
candidate and those of the failures, the 
latter representing over 70% of the total 
cost in 1995.2 
For the pharmaceutical industry to 
survive and flourish, its sales revenue 
must exceed its research, development, 
manufacturing and marketing costs. At 
any stage in the development process, 
the decision whether or not to proceed is, 
in part, determined by the product’s net 
present value (NPV) – the estimate of future 
sales revenue less future development and 
marketing costs. However, sales estimates 
only become reliable when the product is 
close to launch, at which point a company 
will invariably proceed with the marketing of 
the product even if the NPV is insufficiently 
positive to recover costs incurred to date – 
to do otherwise would mean that none of the 
already incurred costs would be recovered.2 It 
comes as no surprise to learn that only 34% 
of new drugs introduced between 1990 and 
1994 registered revenues that exceeded the 
average research and development cost, with 
70% of the industry’s profits coming from 
20% of the products marketed; nevertheless 
the profits generated by the profitable 
candidates more than compensated for the 
losses incurred by the remaining products.4 
In this climate therefore, the need to 
discover ‘blockbuster’ drugs has become more 
significant. In 2003, it was estimated that in 
order to maintain a healthy revenue growth 
rate of 10%, the ten largest pharmaceutical 
companies would need to launch about three 
new compounds per year; however, less than 
two launches per company were actually 
achieved in 2000.5 
The situation is further complicated 
by the fact that patent protection of any 
new discovery is typically 20 years.6 Thus, 
in order to guarantee market protection, 
it is inevitable that companies need to 
take a strategic decision as to the timing 
of the registration of a patent covering 
a new discovery. The earlier the patent 
is registered, the less are the risks that a 
competitor might be the first to market 
a similar discovery, rendering useless all 
research efforts undertaken to date. However, 
given the timeframes involved from product 
discovery to market launch, this means 
that any pharmaceutical company has a 
limited timeframe in which to maximize 
the returns on its investment since upon 
expiry of patent protection, generic versions 
of the medicinal product enter the market. 
The registration requirements for generic 
medicinal products do not require the results 
Thomas Szasz, the leading Hungarian psychiatrist, once stated: 
“Formerly, when religion was strong and science weak, men mistook 
magic for medicine; now, when science is strong and religion weak, 
men mistake medicine for magic.”
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of either toxicological and pharmacological 
tests, or clinical trials to be presented7 
– understandably so since these are largely 
determined by the identity of the medicinal 
product at the molecular level, this being 
the same in both the originator and the 
generic product. Since the product discovery 
and clinical trial costs represent over 80% 
of the expenses incurred in bringing a 
product to market2, it follows that generic 
manufacturing companies can afford to place 
products on the market at significantly lower 
– and thus much more competitive - prices 
than their originator counterparts.
It thus appears that in order to maintain 
a healthy growth rate in the face of rising 
research costs, with the current rate of 
product launch in what is ultimately a fixed 
worldwide market, pharmaceutical companies 
can only generate the necessary revenue 
in a limited time by increasing the market 
prices of their products. Such a solution 
is obviously at odds with the health care 
need and ethical responsibility to provide 
accessibility to medicinal products at a 
reasonable cost, both at the individual 
patient level in the private market and at 
the national level through state-funded 
national health schemes. Many EU member 
states have consequently adopted a series 
of direct and indirect price-setting schemes 
in an attempt to control the extent of such 
price increases and guarantee accessibility, 
whilst not compromising the viability of both 
the originator and generic pharmaceutical 
industry.8 The European Union, whilst 
recognizing that national policies regarding 
the adoption of such measures remained 
the prerogative of the individual member 
states, was also concerned that an excessive 
diversity of measure could unbalance 
intra-Community trade and have a negative 
influence on the functioning of a common 
market in medicinal products. Consequently 
in 1989 the community implemented 
Directive 89/105/EEC with the objective of 
minimizing any disparities in price-control 
measures and ensuring their transparency.9
Discussion
Malta has recently begun the process of 
transposition of this directive into national 
legislation through Legal Notice 58 of 
2009.10 However, efforts to verify the market 
prices of medicinal products date back to 
2007, when a Medicines Committee was 
established by Government for this purpose. 
As a result of an agreement reached by the 
members of the Medicines Committee, it 
was established that prices of medicines in 
the local market were not to be above the 
average price established after comparing 
the prices prevailing in a basket of countries 
made up of three different categories, namely 
high, medium and low-priced categories. 
In a series of three press releases between 
2007 and 2008, the prices of a small number 
of products were reduced to conform to the 
calculated European average11-13, indicating 
that, in the vast majority of cases, prices on 
the local market were indeed close to the 
calculated European average. An analysis 
of the ratio of the unadjusted to adjusted 
market prices for the minority of products 
requiring price adjustment, as quoted in 
the press releases, showed the mean ratio 
between the unadjusted and adjusted 
prices to be 1.173 ± 0.143 (mean ± SD). A 
comparison of the price ratio with respect to 
the highest number of years the medicinal 
product had been authorized in the United 
Kingdom, France or Ireland at the time of 
the comparison exercise was also carried 
out, these countries being chosen due to 
the availability of information in the public 
domain. A statistically significant difference 
(Student’s two-tailed t-parameter = 3.72, p 
<	0.01)	was	seen	to	be	present	between	the	
average price ratios of products that had 
been present in at least one of the three 
markets mentioned for less than 15 years 
(1.063 ± 0.034) and for which no generic 
was present in the Maltese market at the 
time of the exercise, and those that had 
been present for 15 years or more (1.242 ± 
0.149), and for which 40% of the products 
had a generic present in the Maltese market. 
The commencement of the price 
monitoring exercise in Malta was a result of 
the significant awareness of the relativity 
between local market prices and those in 
other countries triggered by the publication 
of the Eurostat review on comparative price 
levels for medicinal products in European 
countries.14 Much attention was focused 
on Malta’s price level index of 1.06, with 
respect to an EU25 average of 1.00, as 
being indicative of the higher prices of 
medicinal products in Malta. Unfortunately, 
the report gave little, if no, indication of 
how such prices impacted public and private 
expenditure on medicinal products at a 
national level. The data given in the Eurostat 
report was simply a comparison of the 
average of the prices of a basket composed 
of the top 181 selling products, divided as 
75% originator products and 25% generic 
products. However, two facts fail to be taken 
into account if one attempts to transpose, 
without further analysis, the numbers of the 
Eurostat report into expenditure on medicinal 
products. The first fact is that patients in 
countries across Europe do not purchase their 
medicinal products in a ratio of 3 originator 
per 1 generic; if this were the case, then 
the market share by volume of generics in 
all EU countries would be 25%. In actual 
fact, figures quoted by the European Generic 
Association15 for generic market shares by 
Figure 1: Scatter plot showing relationship between unadjusted:adjusted price ratio 
and maximum years of registration of product in United Kingdom, Ireland or France, for 
medicinal products whose prices were adjusted in Malta in 2007 and 2008
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volume in EU countries in 2004 varied from 
as low as 4% in Italy (a purchasing ratio 
of 24 originator per 1 generic), to as high 
as 86.5% in Poland (a purchasing ratio of 
approximately 2 originator per 13 generics). 
The second factor is that the ratio of prices 
between originator and generic medicinal 
products varies across Europe too. The fact 
that in 2004, Sweden had a generic market 
share by volume of 39.4% but a market share 
by value of only 12.3% indicates a generic/
originator price ratio of 0.216. At the other 
end of the scale one finds Belgium, where an 
8.7% market share by volume translated into 
a 6.1% market share by value, indicating a 
generic/originator price ratio of 0.682. These 
factors are inapparent if one considers only 
the overall average price: a basket of four 
medicinal products with identical prices of 
€1.00 (price ratio 1.000) would have the 
same average price as a basket of three 
originator products costing €1.30 and one 
generic product costing €0.10 (price ratio 
0.077).
The figures published by the European 
Generics Association for market shares by 
volume allow the division of the 181 product 
base quoted in the Eurostat report into a 
country-specific ratio. Moreover, knowledge 
of both the market shares by volume 
and by value allow the average generic/
originator price ratios for each country to 
be calculated. The combination of these 
figures with the price indices generated in 
the Eurostat report allow the computation 
of country-specific price indices for both 
generic and medicinal products, compared to 
an overall European average of 1.00 (Figure 
2): the results indicate an average European 
originator product price index of 1.072 ± 
0.236, and an average European generic 
product price index of 0.476 ± 0.171, with 
an average generic/originator price ratio of 
0.448 ± 0.139. It is also possible to compute 
the relative expenditure on medicinal 
products in select European countries. 
The results of this computation, in 
comparison with the Eurostat data, are 
shown in Figure 3.
The results of this analysis show that the 
economic impact of the cost of medicines 
does not depend uniquely on the average 
cost of medicines. It also depends on three 
additional factors: the degree of generic 
penetration, the generic/originator ratio of 
Figure 3: Eurostat average price indices and computed expenditure indices in select EU 
countries, compared to a Eurostat overall average of 1.00
Figure 2: Originator and generic medicinal product price indices in select EU countries, 
compared to a Eurostat overall average of 1.00
Abbreviations: country abbreviations as used in figures
DE  Germany 
IE  Ireland 
IT  Italy  
FI  Finland 
NL  Netherlands 
AT  Austria 
BE  Belgium 
SE  Sweden 
UK  United Kingdom
FR  France 
SI  Slovenia 
ES  Spain
HR  Croatia 
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the market prices, and the outlook towards 
generic medicinal products. Austria (1.07) 
and Belgium (1.06) have a similar Eurostat 
average to Malta (1.06). The analysis of 
their market shows them to have moderate 
generic/originator price ratios (0.603 
and 0.682, respectively) and poor generic 
sales (12.3% and 8.7%, respectively). This 
combination leads to the financial impact of 
sales of medicinal products being actually 
higher than the average price would infer 
(1.13 and 1.11, respectively). This situation 
is, in turn, linked to the policies on generic 
drugs present in the two countries: neither 
Austria nor Belgium engage in generic 
promotion and prescriber/public views on 
generics are not favourable.8 
In contrast to the above, one finds 
countries like Netherlands (1.09) and 
Sweden (0.95), with remarkably low generic/
originator price ratios (0.262 and 0.216, 
respectively) and appreciable generic 
sales (48.5% and 39.4%, respectively); 
the financial impact of sales of medicinal 
products is thus lower than the average 
price would indicate (0.86 and 0.82, 
respectively). In contrast to Austria and 
Belgium, the Netherlands and Sweden 
both engage in generic promotion, and 
have a favourable public/prescriber view 
on generics. However, the Netherlands – 
unlike most other European countries – also 
operates a system of reference pricing on 
originator medicinal products, a policy that 
is not favourable towards the establishment 
of market prices by the originator industry 
at a level that will promote its economic 
sustainability. Indeed, an oppressive pricing 
climate for originator medicinal products 
which are under patent protection is clearly 
undesirable, in consideration of the need 
of originator pharmaceutical companies 
to generate revenue in excess of the total 
costs of product discovery and development. 
Thus, the policy of the United Kingdom in 
allowing some degree of freedom, subject to 
profit controls, to originator pharmaceutical 
companies in establishing the market prices 
of new products is recommendable, albeit 
resulting in an originator price index of 1.14. 
The higher originator prices in the United 
Kingdom are counterbalanced by a generic/
originator price ratio of 0.267, and whilst 
such low ratios are unfavourable for the 
sustainability of the generic industry, the 
United Kingdom enjoys a healthy generic 
penetration of 49.3%, achieved by strong 
generic promotion and a positive public/
prescriber view on generics.8 Thus, the United 
Kingdom has a Eurostat average price index of 
0.93 and an even healthier spending index of 
0.73. 
Conclusion
The recommendable situation for Malta 
therefore appears to be one which advocates 
some degree of freedom in market pricing for 
new medicinal products during their on-patent 
life, during which period the budget available 
to the national health insurance schemes 
should aim at supporting the public and private 
expenditure that this policy will engender. 
A valid situation, based on the United 
Kingdom scenario, would appear to involve 
a significantly reduced generic/originator 
price ratio coupled with a high degree of 
generic penetration in the off-patent period 
to ensure that the overall spending index is 
not elevated. However, such low ratios for 
generic products are unlikely to be sustainable 
in a small island state such as Malta, unless 
the market penetration is appreciable. The 
latter can only be achieved through strong 
generic promotion and a campaign to engender 
positive public/prescriber opinions of generics. 
It is a professional and ethical responsibility 
of pharmacists to provide truthful, accurate 
and objective information in the process of 
dispensing medicinal products. In particular, 
great care should be sought to ensure that 
one does not, through one’s actions or words, 
allow the impression to be transmitted that 
lower prices are indicative of a compromise on 
quality, safety and efficacy, as this only serves 
to undermine collegiality and mislead patients, 
to the detriment of the public interest.
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of return on investment needed to sustain economic growth.
•	 Negative	impacts	on	public	and	private	spending	can	be	avoided	through	penetration	of	
lower-priced generics and a positive public/prescriber opinion of generics.
•	 Lower	prices	are	not	indicative	of	a	compromise	on	quality,	safety	and	efficacy.
•	 Pharmacists	have	a	professional	and	ethical	responsibility	to	provide	truthful,	accurate	
and objective information when dispensing medicinal products.
Practice points
